FDA Reverses Course; Will Hold Adcomm for Sarepta’s DMD Gene Therapy

In a reversal of course, the FDA will hold an advisory committee meeting for Sarepta’s investigational gene therapy for Duchenne muscular dystrophy (DMD) ahead of its May 29 action date.